Nab-paclitaxel in combination with carboplatin as first line therapy for patients with stage IIIB/IV NSCLC in the real-world setting: Interim results of the NEPTUN study. 2. Oktober 2018 Dechow, T., Riera-Knorrenschild, J., Schulz, H., Janssen, J., Chiabudini, M., Koszinowski, S., Potthoff, K., Lang, S., Runkel, E., 2018. Oncol Res Treat 41 (suppl 4)(P912). First-line pazopanib in poor-risk patients with metastatic renal cell carcinoma. Staehler, M., Panic, A., Merling, M., Vannier, C., Hermann, E., Hogrefe, C., Potthoff, K., Grünwald, V., 2018. Oncol Res Treat 41 (suppl 4)(P606). Weiterlesen Patient-reported outcomes in patients with metastatic renal cell carcinoma treated with systemic first-line therapy: Interim results of the PRO Kidney registry. Kirste, T., Werner, T., Scheffler, M., Hamm, N., Eckert, R., Pelz, H., Fichter, C., Müller, L., Sahlmann, J., Potthoff, K., 2018. Oncol Res Treat 41… Weiterlesen